Mycoplasma PneumoniaePhase 4DOMINONCT07306234
Doxycycline vs. Macrolide for MRMP (DOMINO)
A Phase 4 study testing Doxycycline and Azithromycin in people with Mycoplasma Pneumoniae and Mycoplasma Pneumoniae Pneumonia, run by Young June Choe at 14 sites in South Korea.
Trial summary
The goal of this clinical trial is to learn if doxycycline works to treat pneumonia in children. It focuses on children with Mycoplasma pneumoniae infection that may not respond to standard medicines. Read more about this study
- Who is it for?
- Ages 3 to 17 years
- Conditions the study is for
- Mycoplasma Pneumoniae, Mycoplasma Pneumoniae Pneumonia
- What is being tested?
- Doxycycline and Azithromycin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 208 participants
- Where
- 14 sitesSouth Korea
- Study dates
- 1 Mar 2026to 28 Feb 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age: 3 to 17 years at the time of enrollment.
- Diagnosis: Clinically diagnosed CAP characterized by respiratory symptoms (e.g., fever, cough, auscultatory findings) and chest X-ray confirming pulmonary infiltrates.
- Pathogen: Confirmed MP M. pneumoniae infection via PCR OR strongly suspected infection based on clinical features and epidemiological grounds (e.g., outbreaks among classmates, poor response to prior non-macrolide antibiotics).
- Resistance: Suspected macrolide-resistant M. pneumoniae (MRMP) infection (e.g., during a reported local epidemic of MRMP).
- Timing: Ability to register and initiate the study drug within 72 hours of symptom onset.
Who cannot join
- Prior use of tetracyclines, macrolides, or quinolones for the current illness.
- Complicated pneumonia (e.g., necrosis, empyema, lung abscess) or severe pneumonia requiring immediate intensive care or exhibiting hypoxia (SpO₂ <90%).
- Hypersensitivity or contraindications to macrolides or tetracyclines.
- Severe immunocompromised state or severe underlying lung disease.
- Severe hepatic impairment (AST/ALT >3x upper limits) or severe renal impairment.
Trial locations and contacts
14 sites in 1 country. Contact the study team or a site near you to ask about taking part.
14 sites in 1 country
South Korea14 sites
Department of Pediatrics, Pusan National University School of Medicine, Pusan National University Children's Hospital, Yangsan, Republic of Korea
Busan
Kyo Jin Jo, MD, +82-10-5943-0133, godjkj@nate.com
Department of Pediatrics, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea
Changwon
Kyung-Ran Kim, MD, +82-10-5943-0133, kkran82@gmail.com
Department of Pediatrics, Chosun University College of Medicine, Chosun University Hospital, Gwangju, Republic of Korea
Gwangju
Gahee Kim, MD, +82-10-5943-0133, pauelf01@gmail.com
Department of Pediatrics, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea
Jeju City
Jae Hong Choi, MD, +82-10-5943-0133, pedidongs@gmail.com
Department of Pediatrics, CHA University School of Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea
Seongnam
Taek Jin Lee, MD, +82-10-5943-0133, bjloveu@daum.net
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Seongnam
Hyunju Lee, MD, +82-10-5943-0133, hyunjulee@snu.ac.kr
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Republic of Korea
Seoul
Ui Yoon Choi, MD, +82-10-5943-0133, uiyoon@catholic.ac.kr
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea
Seoul
Hyun Mi Kang, MD, +82-10-5943-0133, pedhmk@catholic.ac.kr
Department of Pediatrics, Eulji University School of Medicine, Eulji University Hospital, Seoul, Republic of Korea
Seoul
Byung Wook Eun, MD, +82-10-5943-0133
Department of Pediatrics, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
Seoul
Youn Young Choi, MD, +82-10-5943-0133, cyypedr@korea.ac.kr
Department of Pediatrics, Korea University College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
Seoul
Yoon Sun Yoon, MD, +82-10-5943-0133, yhappy815@gmail.com
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Republic of Korea
Seoul
Ki Wook Yun, MD, +82-10-5943-0133, pedwilly@snu.ac.kr
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Republic of Korea
Seoul
Bin Ahn, MD, +82-10-5943-0133, ahnnybinny@gmail.com
Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea
Seoul
Doo Ri Kim, MD, +82-10-5943-0133, doori756.kim@samsung.com
About this study
Official title: Efficacy and Safety of Doxycycline Versus Macrolides for Mycoplasma Pneumoniae Infection in Children (DOMINO): A Protocol for a Multicenter, Randomized, Open-Label, Superiority Trial
The goal of this clinical trial is to learn if doxycycline works to treat pneumonia in children. It focuses on children with Mycoplasma pneumoniae infection that may not respond to standard medicines. The main questions it aims to answer are:
- Does doxycycline stop fevers faster than azithromycin?
- Is doxycycline safe for children, specifically regarding tooth color changes?
Read more
Researchers will compare doxycycline to azithromycin to see if doxycycline works better to treat this type of pneumonia.
Participants will:
- Take either doxycycline or azithromycin by mouth for 7 to 14 days.
- Check their body temperature to see when their fever goes away.
- Visit the hospital to check for any medical problems.
- Have their teeth checked for color changes 28 days after starting the medicine.
- Being tested
- Doxycycline, Azithromycin
- Keywords
- Mycoplasma pneumoniae, Macrolide resistance, Children
- Medical subject headings
- Pneumonia, Mycoplasma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DoxycyclineDrug
Intervention Group (Doxycycline): Participants will receive oral doxycycline (4 mg/kg/day divided into 2 doses for weight ≤45 kg; 100 mg BID for weight >45 kg). The standard treatment duration is 7 days, which may be extended up to 14 days based on clinical response.
AzithromycinDrug
Control Group (Azithromycin): Participants will receive oral azithromycin according to the standard 5-day regimen (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5).
Rescue Therapy Protocol: To ensure patient safety, a standardized "rescue therapy" protocol is implemented. Participants in the Control group who fail to demonstrate clinical improvement at the 48-72 hour assessment-defined as persistent fever (≥38.0°C) or clinical deterioration-will be immediately switched to doxycycline. Consistent with the intention-to-treat principle, these cases will be classified as treatment failures for the primary efficacy analysis.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group (Doxycycline) | Experimental | Participants will receive oral doxycycline (4 mg/kg/day divided into 2 doses for weight ≤45 kg; 100 mg BID for weight >45 kg). The standard treatment duration is 7 days, which may be extended up to 14 days based on clinical response. Receives: Drug: Doxycycline |
| Control Group (Azithromycin) | Active comparator | Participants will receive oral azithromycin according to the standard 5-day regimen (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5). Receives: Drug: Azithromycin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Defervescence rate
Defervescence rate at 72 hours. Defervescence is defined as the maintenance of body temperature below 38.0°C for at least 24 consecutive hours without antipyretics.
Measured: 72 hours
Secondary outcomes (7)
Hospitalization Rate
Percentage of participants requiring hospitalization due to the progression of pneumonia or complications.
Measured: Up to 30 days
Length of Hospital Stay
The duration of hospitalization from admission to discharge.
Measured: Up to 30 days
Hospital Readmission Rate
Percentage of participants readmitted to the hospital after initial discharge due to worsening of pneumonia.
Measured: Up to 30 days
Treatment Failure Rate at Day 7
Treatment failure is defined as the occurrence of any of the following: need for rescue therapy (switching to doxycycline for the control group), addition of other antibiotics or systemic steroids, or clinical deterioration requiring intensive care unit (ICU) admission.
Measured: 7 days
Time to Resolution of Respiratory Symptoms
Time to resolution of respiratory symptoms (cough, dyspnea) assessed using a 4-point Likert scale. Resolution is defined as the point at which the symptom score reaches 0 (none) or 1 (mild) and is maintained
Measured: Up to 30 days
Time to Radiological Resolution of Infiltrates
Time to resolution of pulmonary infiltrates as confirmed by chest radiography follow-up.
Measured: Up to 30 days
Incidence of Tooth Discoloration in Children Under 8 Years
Assessment of visible tooth discoloration evaluated by visual inspection.
Measured: Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start1 Mar 2026 (estimated)
- Primary completion31 Jan 2029 (estimated)
- Study completion28 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Mycoplasma PneumoniaeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Young June Choe
- Sponsor type
- University, hospital or other
- Collaborators
- Korea Society of Pediatric Infectious Diseases, National Institute of Health, Korea, Korea Disease Control and Prevention Agency, DT&CRO
- Responsible party
- Sponsor-investigator, Young June Choe, Korea University Anam Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07306234
- Sponsor's protocol ID
- DOMINO
- Other IDs
- KNIH
- Acronym
- DOMINO
- Status last verified
- Dec 2025
- First submitted
- 22 Dec 2025
- Last updated
- 29 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) that underlie the results reported in the publication will be made available to researchers who provide a methodologically sound proposal. This includes text, tables, figures, and appendices. IPD will be available beginning 6 months and ending 36 months following article publication. Supporting Information: The study protocol, statistical analysis plan (SAP), and informed consent form will also be shared. Access Criteria: Proposals should be directed to the Principal Investigator at \[Insert Official Email Address\]. To gain access, data requestors will need to sign a data access agreement.
Publications
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134. doi: 10.1086/508667. Epub 2006 Oct 2.
PubMed 17029130Cummings MM. Copyright and reproduction. Bull Med Libr Assoc. 1973 Jul;61(3):344-5. No abstract available.
PubMed 4725345Kang DH, Lee JY, Chung JH, Cho JM, Lee SH, Park J, Kim TH, Yoo TK, Lee SW. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012 Aug;66(8):813-820. doi: 10.1111/j.1742-1241.2012.02946.x.
PubMed 22805273Xue H, Xu H, Song X, Chen M, Wang X, Ji M, Wang M. Porous Frustrated Lewis Pairs Catalyst Constructed on Defective Zirconium-Based Metal-Organic Frameworks for Hydrogenation Reactions with H2. Inorg Chem. 2024 Aug 26;63(34):16011-16017. doi: 10.1021/acs.inorgchem.4c02470. Epub 2024 Aug 15.
PubMed 39145892Guo T, Zamuner F, Ting S, Chen L, Rooper L, Tamayo P, Fakhry C, Gaykalova D, Mehra R. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma. Front Oncol. 2024 Mar 5;14:1336577. doi: 10.3389/fonc.2024.1336577. eCollection 2024.
PubMed 38505587Forde E, Humphreys H, Greene CM, Fitzgerald-Hughes D, Devocelle M. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob Agents Chemother. 2014;58(2):978-85. doi: 10.1128/AAC.01167-13. Epub 2013 Nov 25.
PubMed 24277028Liu Y. [Lay further emphasis on the cosmetic repair of deep burn wounds in extraordinary regions or caused by uncommon agents]. Zhonghua Shao Shang Za Zhi. 2014 Oct;30(5):389-91. Chinese.
PubMed 25572886Jiao R, Xue B, Zhang M. A Multiform Optimization Framework for Constrained Multiobjective Optimization. IEEE Trans Cybern. 2023 Aug;53(8):5165-5177. doi: 10.1109/TCYB.2022.3178132. Epub 2023 Jul 18.
PubMed 35687640Han S, Luo Y, Liu B, Guo T, Qin D, Luo F. Dietary flavonoids prevent diabetes through epigenetic regulation: advance and challenge. Crit Rev Food Sci Nutr. 2023 Nov;63(33):11925-11941. doi: 10.1080/10408398.2022.2097637. Epub 2022 Jul 11.
PubMed 35816298Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005 Jun;49(6):2302-6. doi: 10.1128/AAC.49.6.2302-2306.2005.
PubMed 15917525Tolbert K, Stubbs E. Rational use of gastroprotectants in cats: An evidence-based approach. J Feline Med Surg. 2024 Aug;26(8):1098612X241274235. doi: 10.1177/1098612X241274235.
PubMed 39105658MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.
PubMed 23459495Roddy SP, Darling RC 3rd, Chang BB, Kreienberg PB, Paty PS, Lloyd WE, Shah DM. Brachial artery reconstruction for occlusive disease: a 12-year experience. J Vasc Surg. 2001 Apr;33(4):802-5. doi: 10.1067/mva.2001.112705.
PubMed 11296335Choi YY, Kang C, Choe YJ, Yoo Y, Shin A, Kim DR, Ahn B, Eun BW, Kim G, Kang HM, Kim YJ, Cho YK, Lee H, Kim YK, Choi JH, Yun KW, Jo KJ, Kim KR, Lee TJ, Choi UY, Yoon YS, Kim J, Kang MS, Park SK, Yang WM, Lee S. Efficacy and safety of Doxycycline versus Macrolides for Mycoplasma pneumoniae INfectiOn in Children (DOMINO): a protocol for a multicentre, randomised, open-label, superiority trial. BMJ Open. 2026 May 26;16(5):e117862. doi: 10.1136/bmjopen-2026-117862.
PubMed 42191206
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Doxycycline Versus Macrolides for Mycoplasma Pneumoniae Infection in Children (DOMINO): A Protocol for a Multicenter, Randomized, Open-Label, Superiority Trial
- ClinicalTrials.gov ID
- NCT07306234
- Acronym / sponsor ID
- DOMINO / DOMINO
- Keywords
- Mycoplasma pneumoniae, Macrolide resistance, Children
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 208 participants (estimated)
- Lead sponsor
- Young June ChoeUniversity, hospital or other
- Collaborators
- Korea Society of Pediatric Infectious Diseases, National Institute of Health, Korea, Korea Disease Control and Prevention Agency, DT&CRO
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 31 Jan 2029 (estimated)
- Study completion
- 28 Feb 2029 (estimated)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if doxycycline works to treat pneumonia in children. It focuses on children with Mycoplasma pneumoniae infection that may not respond to standard medicines. The main questions it aims to answer are:
- Does doxycycline stop fevers faster than azithromycin?
- Is doxycycline safe for children, specifically regarding tooth color changes?
Researchers will compare doxycycline to azithromycin to see if doxycycline works better to treat this type of pneumonia.
Participants will:
- Take either doxycycline or azithromycin by mouth for 7 to 14 days.
- Check their body temperature to see when their fever goes away.
- Visit the hospital to check for any medical problems.
- Have their teeth checked for color changes 28 days after starting the medicine.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group (Doxycycline) | Experimental | Drug: DoxycyclineParticipants will receive oral doxycycline (4 mg/kg/day divided into 2 doses for weight ≤45 kg; 100 mg BID for weight >45 kg). The standard treatment duration is 7 days, which may be extended up to 14 days based on clinical response. |
| Control Group (Azithromycin) | Active comparator | Drug: AzithromycinParticipants will receive oral azithromycin according to the standard 5-day regimen (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5). |
Who may qualify
- Ages
- 3 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Age: 3 to 17 years at the time of enrollment.
- Diagnosis: Clinically diagnosed CAP characterized by respiratory symptoms (e.g., fever, cough, auscultatory findings) and chest X-ray confirming pulmonary infiltrates.
- Pathogen: Confirmed MP M. pneumoniae infection via PCR OR strongly suspected infection based on clinical features and epidemiological grounds (e.g., outbreaks among classmates, poor response to prior non-macrolide antibiotics).
- Resistance: Suspected macrolide-resistant M. pneumoniae (MRMP) infection (e.g., during a reported local epidemic of MRMP).
- Timing: Ability to register and initiate the study drug within 72 hours of symptom onset.
Key exclusion criteria (5 listed)
- Prior use of tetracyclines, macrolides, or quinolones for the current illness.
- Complicated pneumonia (e.g., necrosis, empyema, lung abscess) or severe pneumonia requiring immediate intensive care or exhibiting hypoxia (SpO₂ <90%).
- Hypersensitivity or contraindications to macrolides or tetracyclines.
- Severe immunocompromised state or severe underlying lung disease.
- Severe hepatic impairment (AST/ALT >3x upper limits) or severe renal impairment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DoxycyclineIntervention Group (Doxycycline): Participants will receive oral doxycycline (4 mg/kg/day divided into 2 doses for weight ≤45 kg; 100 mg BID for weight >45 kg). The standard treatment duration is 7 days, which may be extended up to 14 days based on clinical response. | Drug | Intervention Group (Doxycycline) |
| AzithromycinControl Group (Azithromycin): Participants will receive oral azithromycin according to the standard 5-day regimen (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5). Rescue Therapy Protocol: To ensure patient safety, a standardized "rescue therapy" protocol is implemented. Participants in the Control group who fail to demonstrate clinical improvement at the 48-72 hour assessment-defined as persistent fever (≥38.0°C) or clinical deterioration-will be immediately switched to doxycycline. Consistent with the intention-to-treat principle, these cases will be classified as treatment failures for the primary efficacy analysis. | Drug | Control Group (Azithromycin) |
Primary outcome
Defervescence rate
Time frame: 72 hours
Defervescence rate at 72 hours. Defervescence is defined as the maintenance of body temperature below 38.0°C for at least 24 consecutive hours without antipyretics.
7 secondary outcomes
Hospitalization Rate
Time frame: Up to 30 days
Length of Hospital Stay
Time frame: Up to 30 days
Hospital Readmission Rate
Time frame: Up to 30 days
Treatment Failure Rate at Day 7
Time frame: 7 days
Time to Resolution of Respiratory Symptoms
Time frame: Up to 30 days
Time to Radiological Resolution of Infiltrates
Time frame: Up to 30 days
Incidence of Tooth Discoloration in Children Under 8 Years
Time frame: Day 28
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2025.
- Results publication: PubMed 17029130Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134. doi: 10.1086/508667. Epub 2006 Oct 2.
- Results publication: PubMed 4725345Cummings MM. Copyright and reproduction. Bull Med Libr Assoc. 1973 Jul;61(3):344-5. No abstract available.
- Results publication: PubMed 22805273Kang DH, Lee JY, Chung JH, Cho JM, Lee SH, Park J, Kim TH, Yoo TK, Lee SW. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012 Aug;66(8):813-820. doi: 10.1111/j.1742-1241.2012.02946.x.
- Results publication: PubMed 39145892Xue H, Xu H, Song X, Chen M, Wang X, Ji M, Wang M. Porous Frustrated Lewis Pairs Catalyst Constructed on Defective Zirconium-Based Metal-Organic Frameworks for Hydrogenation Reactions with H2. Inorg Chem. 2024 Aug 26;63(34):16011-16017. doi: 10.1021/acs.inorgchem.4c02470. Epub 2024 Aug 15.
- Results publication: PubMed 38505587Guo T, Zamuner F, Ting S, Chen L, Rooper L, Tamayo P, Fakhry C, Gaykalova D, Mehra R. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma. Front Oncol. 2024 Mar 5;14:1336577. doi: 10.3389/fonc.2024.1336577. eCollection 2024.
- Results publication: PubMed 24277028Forde E, Humphreys H, Greene CM, Fitzgerald-Hughes D, Devocelle M. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob Agents Chemother. 2014;58(2):978-85. doi: 10.1128/AAC.01167-13. Epub 2013 Nov 25.
- Results publication: PubMed 25572886Liu Y. [Lay further emphasis on the cosmetic repair of deep burn wounds in extraordinary regions or caused by uncommon agents]. Zhonghua Shao Shang Za Zhi. 2014 Oct;30(5):389-91. Chinese.
- Results publication: PubMed 35687640Jiao R, Xue B, Zhang M. A Multiform Optimization Framework for Constrained Multiobjective Optimization. IEEE Trans Cybern. 2023 Aug;53(8):5165-5177. doi: 10.1109/TCYB.2022.3178132. Epub 2023 Jul 18.
- Results publication: PubMed 35816298Han S, Luo Y, Liu B, Guo T, Qin D, Luo F. Dietary flavonoids prevent diabetes through epigenetic regulation: advance and challenge. Crit Rev Food Sci Nutr. 2023 Nov;63(33):11925-11941. doi: 10.1080/10408398.2022.2097637. Epub 2022 Jul 11.
- Results publication: PubMed 15917525Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005 Jun;49(6):2302-6. doi: 10.1128/AAC.49.6.2302-2306.2005.
- Results publication: PubMed 39105658Tolbert K, Stubbs E. Rational use of gastroprotectants in cats: An evidence-based approach. J Feline Med Surg. 2024 Aug;26(8):1098612X241274235. doi: 10.1177/1098612X241274235.
- Results publication: PubMed 23459495MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) that underlie the results reported in the publication will be made available to researchers who provide a methodologically sound proposal. This includes text, tables, figures, and appendices. IPD will be available beginning 6 months and ending 36 months following article publication. Supporting Information: The study protocol, statistical analysis plan (SAP), and informed consent form will also be shared. Access Criteria: Proposals should be directed to the Principal Investigator at [Insert Official Email Address]. To gain access, data requestors will need to sign a data access agreement.
Related trials for Mycoplasma Pneumoniae
Enrolling by invitationObservational study
Comparative Autoantibody and Immunologic Cell Marker Study
Autoimmune Diseases, Lupus Erythematosus, Systemic
Not yet recruitingObservational study
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
Community-Acquired Pneumonia
Recruiting
A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study
Community Acquired Pneumonia in Children, Mycoplasma Pneumoniae
Active, not recruitingObservational study
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
SARS CoV 2 Infection, RSV Infection
Active, not recruiting
Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
Respiratory Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Doxycycline and Azithromycin in people with Mycoplasma Pneumoniae and Mycoplasma Pneumoniae Pneumonia, run by Young June Choe at 14 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Young June Choe, MD (+82-10-5943-0133, choey@korea.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Defervescence rate (time frame: 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07306234, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2025.